Immunocytochemical markers in stage I lung cancer: relevance to prognosis - PubMed (original) (raw)
Immunocytochemical markers in stage I lung cancer: relevance to prognosis
U Pastorino et al. J Clin Oncol. 1997 Aug.
Abstract
Purpose: This study investigated the frequency of the expression and prognostic significance of a panel of immunocytochemical markers in resected non-small-cell lung cancer (NSCLC).
Patients and methods: A total of 515 cases of pathologic stage I NSCLC were analyzed. The median follow-up time of surviving patients was 102 months. The following immunocytochemical markers were tested: blood group A and precursors of blood antigens; laminin receptor; c-erbB1/epidermal growth factor receptor (EGFR) and c-erbB2/Neu; BCl2; p53; and angiogenesis. Kaplan-Meier estimates of survival and time to recurrence were calculated for clinical variables and biologic markers using the Cox model for multivariate analysis.
Results: The pathologic tumor extension (pT) represented the most powerful prognostic factor for survival (P = .0008) and time to recurrence (P = .0007). None of the immunocytochemical markers emerged as an independent predictive factor for survival. Bcl2-positive tumors showed a better time to recurrence (P = .03), but the difference lost statistical significance in the multivariate analysis. Of interest, in the group of 137 patients classified as pT1N0, both EGFR expression and nonangiogenic type of vascular pattern were associated with a poorer survival (P = .02). However, data derived from subset analysis must be interpreted cautiously.
Conclusion: Our findings do not support a relevant prognostic role of immunocytochemical markers in NSCLC. The evidence is not sufficient to alter clinical practice or even to restrict clinical trials of adjuvant treatments to predefined biologic subsets of patients.
Similar articles
- Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, Marie B, Farré G, Labib T, Pottier G, Sesboüé R, Bronner C, Vignaud JM, Martinet Y, Martinet N. Moldvay J, et al. Clin Cancer Res. 2000 Mar;6(3):1125-34. Clin Cancer Res. 2000. PMID: 10741743 - Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL, Gatter KC. Giatromanolaki A, et al. Clin Cancer Res. 1998 Dec;4(12):3017-24. Clin Cancer Res. 1998. PMID: 9865915 - Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery.
Carbognani P, Tincani G, Crafa P, Sansebastiano G, Pazzini L, Zoni R, Bobbio A, Rusca M. Carbognani P, et al. J Cardiovasc Surg (Torino). 2002 Aug;43(4):545-8. J Cardiovasc Surg (Torino). 2002. PMID: 12124571 - Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung.
Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT, Sugarbaker DJ. Strauss GM, et al. J Clin Oncol. 1995 May;13(5):1265-79. doi: 10.1200/JCO.1995.13.5.1265. J Clin Oncol. 1995. PMID: 7738631 Review. - Prognostic factors in NSCLC. Recent experiences.
van Zandwijk N, Mooi WJ, Rodenhuis S. van Zandwijk N, et al. Lung Cancer. 1995 Apr;12 Suppl 1:S27-33. doi: 10.1016/0169-5002(95)00418-z. Lung Cancer. 1995. PMID: 7551931 Review.
Cited by
- EPMA position paper in cancer: current overview and future perspectives.
Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, Vittadini G, Desiderio DM. Grech G, et al. EPMA J. 2015 Apr 15;6(1):9. doi: 10.1186/s13167-015-0030-6. eCollection 2015. EPMA J. 2015. PMID: 25908947 Free PMC article. - Overview on the Different Patterns of Tumor Vascularization.
Ribatti D, Pezzella F. Ribatti D, et al. Cells. 2021 Mar 13;10(3):639. doi: 10.3390/cells10030639. Cells. 2021. PMID: 33805699 Free PMC article. Review. - Mind-mapping for lung cancer: towards a personalized therapeutics approach.
Mollberg N, Surati M, Demchuk C, Fathi R, Salama AK, Husain AN, Hensing T, Salgia R. Mollberg N, et al. Adv Ther. 2011 Mar;28(3):173-94. doi: 10.1007/s12325-010-0103-9. Epub 2011 Feb 9. Adv Ther. 2011. PMID: 21337123 Free PMC article. Review. - Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non-small-cell lung cancer patients.
Koufos N, Syrios J, Michailidou D, Xynos ID, Lazaris A, Kavantzas N, Tomos P, Kakaris S, Kosmas C, Tsavaris N. Koufos N, et al. Mol Clin Oncol. 2016 Oct;5(4):440-446. doi: 10.3892/mco.2016.966. Epub 2016 Jul 27. Mol Clin Oncol. 2016. PMID: 27699040 Free PMC article. - Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas.
Passalidou E, Trivella M, Singh N, Ferguson M, Hu J, Cesario A, Granone P, Nicholson AG, Goldstraw P, Ratcliffe C, Tetlow M, Leigh I, Harris AL, Gatter KC, Pezzella F. Passalidou E, et al. Br J Cancer. 2002 Jan 21;86(2):244-9. doi: 10.1038/sj.bjc.6600015. Br J Cancer. 2002. PMID: 11870514 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous